CD22 and Parkinson disease: Additionally, in 2021, α7nAChR agonists (e.g., ABT‐126) demonstrated promising Phase II clinical results in schizophrenia [31], while the successful reduction of CSF α‐synuclein (α‐syn) levels in patients with Parkinson's disease (PD) has been achieved using the PD01A vaccine [32], and recent findings have demonstrated that CD22‐targeted sulesomab enhances microglial Aβ phagocytosis while suppressing neuroinflammation in AD [33].